Drug Prices Unaffected By Senate Supply Chain, Compounding Bill, CBO Indicates
This article was originally published in The Pink Sheet Daily
No mention of affects to Medicare, Medicaid in the CBO score for the Senate compounding and supply chain bill, but FDA is likely to need more budget authority given that expected user fee revenues are not expected to cover the full costs of the new programs.
You may also be interested in...
HELP Committee leaders Harkin and Alexander write letter arguing that FDA’s warnings of more problems from tainted compounded medications have come true and that their legislation should gain a vote next month.
Safeguarding America’s Pharmaceuticals Act passes on suspension calendar, but likely sets up fight with Senate in conference.
Industry groups will continue to search for legislative vehicles to move a national standard that would preempt state laws; near-term, though, manufacturers and distributors must prepare for California pedigree law.